



Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521

Email : influxhealthtech@gmail.com / influxhealthcare1@gmail.com

Website : www.influxhealthtech.com

CIN : U24299MH2020PLC346825

January 29, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code – INFLUX

Dear Sir/Ma'am,

Sub: Business Update for the Quarter & Nine Months Ended December 31, 2025 (Q3 & 9M FY26)

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Business Update – Q3 FY26

Innovation-Led Growth Driving Value Creation

Influx Healthtech Limited continued its strong growth momentum during **Q3 FY26**, reflecting a strategic transition from a volume-led CDMO to a value-led innovation partner. The performance was supported by healthy year- on-year growth, improved capacity utilization, and a higher share of value-added formulations.

Q3 FY26 Highlights

1. Robust Operational Performance

- The quarter witnessed robust operational performance, supported by healthy year-on-year growth.
- The quarter witnessed a better product mix driven by **clinical nutrition** and **specialty formats**.
- Margin profiles improved due to a focus on proprietary formats, complex delivery systems, and

operational cost rationalization.

- Performance was driven by:
 - Higher utilization of **nutraceutical** and **cosmetic** manufacturing lines.
 - Successful commercialization of new clinical nutrition formats.
 - Repeat orders from long-standing clients and expansion into mid-size/emerging brands.

2. Capacity & Technology Expansion Supporting Growth

The Company is focusing its Capex on high-ROI, differentiation-led investments to enhance its competitive edge:

- **Specialty Manufacturing:** Expanding infrastructure for Nutraceutical and Veterinary categories.
- **Automation:** Implementing process optimization to improve consistency, yield, and scalability.
- **Technology Breakthroughs:** Introduction of the **Quick Snap™ Machine**, enabling precision dosing and single-serve nutrition/cosmetic delivery.

3. Order Book & Execution Visibility

Influx Healthtech enters Q4 with a strengthened order book and clear revenue visibility. Key drivers include:

- **New Product Launches:** High-calorie nutritional pastes, vegan protein water and color- changing sunscreens.
- **Customer Onboarding:** Increased enquiries and onboarding of **D2C wellness brands** and **clinical nutrition startups**.
- **Scale-up Pipeline:** Strong conversion pipeline for Q4 FY26 and into FY27.

4. Outlook – Q4 FY26 and Beyond

The management expects the execution momentum to continue into the final quarter, driven by:

- Commercial rollout of products developed in previous quarters.
- Improved contribution from **innovation-led SKUs** and specialty formats.
- **FY27 Strategy:** Positioned as a "scale + innovation" year, focusing on higher wallet share from existing customers and entry into complex premium categories.

Strategic Focus Areas

- **Clinical & Functional Nutrition:** Expanding into Medical nutrition (GLP-1 support) and sports nutrition.
- **Cosmetic Innovation:** Developing advanced delivery systems and high-sensory formulations.
- **Operational Excellence:** Continuous focus on compliance-led growth and backward integration



Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521
Email : influxhealthtech@gmail.com / influxhealthcare1@gmail.com
Website : www.influxhealthtech.com
CIN : U24299MH2020PLC346825

The above information is subject to limited review / audit by the Statutory Auditors of the Company. The Company will continue to keep the stock exchanges informed of all material developments in compliance with applicable regulations.

We request you to take the above information on record.

Thanking you,

For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

For further information, please contact



Company
Influx Healthtech Limited
Ashish Shah
Chief Financial Officer
cs@influxhealthtech.com



Investor relations consultants
Capital Bridge Advisory Service Private Limited
+91 79 4594 0516
info@capbridge.in